Methicillin-Susceptible Staphylococcus Aureus Market: By Treatment & By Geography - Forecast 2016-2021

  • ID: 3973757
  • Report
  • 145 pages
  • IndustryARC
1 of 3
Methicillin-susceptible staphylococcus aureus (MSSA) infections are the infections caused by gram-positive bacterium, which leads to skin allergies, pneumonia and endocarditis. Globally, rising rate of morbidity and mortality of the methicillin-susceptible staphylococcus aureus infection, increasing research and development activities for developing more efficient and less time consuming drugs, rise in the awareness among people regarding diagnosis and treatment of methicillin-susceptible staphylococcus aureus infection, and increasing government initiative across the globe are the prime growth drivers of global methicillin-susceptible staphylococcus aureus market. In addition, increase in adoption of methicillin-susceptible staphylococcus aureus treatment in emerging economies such as China, India and others, will create new opportunities for global methicillin-susceptible staphylococcus aureus market. However, higher cost of the research and development, and complex government approval process are the key restraints for global methicillin-susceptible staphylococcus aureus market.

Geographically Europe dominated global methicillin-susceptible staphylococcus aureus market, followed by North America because of higher prevalence of methicillin-susceptible staphylococcus aureus infection in these regions, availability of healthcare infrastructure, extensive government support for development of drugs, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the treatment, semi synthetic penicillin has the highest market share in global methicillin-susceptible staphylococcus aureus market due.

This report identifies the global methicillin-susceptible staphylococcus aureus market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global methicillin-susceptible staphylococcus aureus market.

This report segments global methicillin-susceptible staphylococcus aureus market on the basis of treatment, and regional market as follows:

Methicillin-Susceptible Staphylococcus Aureus Market, By Treatment: Semi-synthetic penicillin, Cephalosporins, Vancomycin, Linezolid, and Daptomycin
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the methicillin-susceptible staphylococcus aureus market. Some of the major companies’ profiles in detail are as follows:

Dainippon Sumitomo Pharma Co., Ltd
Immtech Pharmaceuticals, Inc.

Lytix Biopharma AS
PharmaIN Corporation
Cubist Pharmaceuticals
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Methicillin-Susceptible Staphylococcus Aureus Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Methicillin-Susceptible Staphylococcus Aureus Market– Market Forces
4.1. Drivers
4.1.1. Rising rate of morbidity and mortality of the methicillin-susceptible staphylococcus aureus infection
4.1.2. Increasing research and development activities for developing more efficient and less time consuming drugs
4.2. Restraints
4.2.1. Higher cost of research and development
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Methicillin-Susceptible Staphylococcus Aureus Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Methicillin-Susceptible Staphylococcus Aureus Market, By Treatment
6.1. Semi-synthetic penicillin
6.2. Cephalosporins
6.3. Vancomycin
6.4. Linezolid
6.5. Daptomycin

7. Methicillin-Susceptible Staphylococcus Aureus Market, By Geography
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW

8. Methicillin-Susceptible Staphylococcus Aureus – Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract

9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Dainippon Sumitomo Pharma Co., Ltd
9.2. Immtech Pharmaceuticals, Inc.
9.3. Lytix Biopharma AS
9.4. PharmaIN Corporation
9.5. Cubist Pharmaceuticals
9.6. Kenta Biotech AG
9.7. Arsanis Biosciences GmbH
9.8. Volcano Corporation
9.9. Abbott Vascular
9.10. Angioscore Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Bibliography
10.5. Compilation of Expert Insights
10.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll